Akums Drugs and Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO), has announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO (Central Drugs Standard Control Organization), India  and the United States Food and Drug Administration (USFDA).

Pregnancy-related nausea and vomiting impact 70–80% of women, and for some, the symptoms persist beyond the first trimester, potentially leading to hyperemesis gravidarum (HG) if left untreated.

Research indicates that pregnant women experiencing HG face an elevated risk of adverse maternal and fetal outcomes, particularly if marked by significant weight loss, severe symptoms, or a failure to gain weight over consecutive trimesters. While the exact cause of hyperemesis gravidarum remains largely elusive, various theories exist, as detailed in the pathophysiology. Nevertheless, certain risk factors are associated with the development of hyperemesis during pregnancy.

Doxylamine, a competitive histamine H1 receptor inhibitor with sedative and anticholinergic effects, is paired with Pyridoxine Hydrochloride (Vitamin B6), known for its anti-emetic properties and its role in haemoglobin production and neurotransmitter metabolism. This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy, ensuring better outcomes for both mothers and infants.